A comprehensive view of FDA Drug / Device Reviews. This page highlights a small sample of our full coverage.
For real-time access, please log in to your Government & Public Policy Market Intelligence Service.

Recent Articles

sample of recent headlines, press releases and get more..

Eisai and Biogen disappointed by EMA's negative opinion on lecanemab for early Alzheimer's; the humanized anti-amyloid-beta monoclonal antibody was under review for mild cognitive impairment
Published: July 26, 2024 by Biogen Inc.
FDA Advisory Committee reviewed AstraZeneca’s Imfinzi for resectable lung cancer; AEGEAN Phase III trial shows 32% risk reduction in recurrence, progression, or death vs. chemotherapy alone
Published: July 25, 2024 by AstraZeneca AB
AskBio secures FDA Fast Track and UK MHRA Innovation Passport for AB-1005 gene therapy; AB-1005 targets moderate Parkinson’s disease with ongoing Phase II REGENERATE-PD trial expansion in the U.S. and EU
Published: July 11, 2024 by Bayer AG
FDA approves Lilly's Kisunla™ for early symptomatic Alzheimer's; pivotal Phase 3 study showed up to 35% cognitive decline reduction over 18 months, 39% lower risk of disease progression
Published: July 02, 2024 by Eli Lilly & Co.
Lupin receives tentative U.S. FDA approval for Olopatadine Hydrochloride Ophthalmic Solution, 0.7%; product is a generic equivalent of Pataday® Once Daily Relief, expected annual U.S. sales USD 22 million
Published: June 27, 2024 by Contify Life Science News

Ask us about our Government & Public Policy market view

Trending Chart

Interactive chart with headline count